# Adaptive Dengue Antiviral Platform Trial

> **NCT06551844** · PHASE2 · RECRUITING · sponsor: **Oxford University Clinical Research Unit, Vietnam** · enrollment: 500 (estimated)

## Conditions studied

- Dengue
- Antiviral Drugs

## Interventions

- **DRUG:** Molnupiravir 400 mg
- **DRUG:** VIS513 (a monoclonal antibody)
- **DRUG:** Remdesivir 100mg

## Key facts

- **NCT ID:** NCT06551844
- **Lead sponsor:** Oxford University Clinical Research Unit, Vietnam
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551844, "Adaptive Dengue Antiviral Platform Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06551844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*